Genmab — Juli 2016
-
Er det her relevant info: J&J bags CD28 antagonist from OSE in €155M autoimmune deal
Tuesday, July 5, 2016Johnson & Johnson has exercised its option to license FR104 from OSE Immunotherapeutics. The agreement, which follows shortly after the conclusion of a Phase I trial of FR104, sees J&J commit to pay up to €155 million for the global rights to the CD28 antagonist in autoimmune diseases and transplantations.
-
God morgen.
-
Medicinalaktier med USA fokus bør ikke rystes så meget som så meget andet i den nuværende situation.
-
Enig.
-
Nordnet sælger og A/B køber her i åbningen.
-
Nordea om J&J"Johnson & Johnson (+0,8%) klarer uroen i fin stil og har gennem længere tid klaret
sig bedre end både sektoren og markedet generelt. Når der er lidt uro på markederne,
får investorerne for alvor øjnene op for Johnson & Johnsons kvaliteter. Selskabet
har en stærk og bred produktportefølje og en spændende pipeline af nye
produkter og leverer en støt stigende indtjening. Kontantbeholdningen er stor og giver mulighed for værdiskabende opkøb, når mulighederne byder sig, samtidig med at
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind